Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Net Income towards Common Stockholders (2016)

Lixte Biotechnology Holdings' Net Income towards Common Stockholders history spans 7 years, with the latest figure at -$516257.0 for Q4 2016.

  • For Q4 2016, Net Income towards Common Stockholders changed N/A year-over-year to -$516257.0; the TTM value through Dec 2016 reached -$2.1 million, up 4.63%, while the annual FY2025 figure was -$5.1 million, 42.62% down from the prior year.
  • Net Income towards Common Stockholders reached -$516257.0 in Q4 2016 per LIXT's latest filing, up from -$646936.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$313051.0 in Q3 2013 to a low of -$11.2 million in Q4 2013.
  • Average Net Income towards Common Stockholders over 5 years is -$1.7 million, with a median of -$536124.0 recorded in 2014.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 62.65% in 2013, then crashed 115.08% in 2014.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$9.8 million in 2012, then dropped by 13.99% to -$11.2 million in 2013, then skyrocketed by 95.53% to -$501393.0 in 2014, then tumbled by 55.5% to -$779687.0 in 2015, then soared by 33.79% to -$516257.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Net Income towards Common Stockholders are -$516257.0 (Q4 2016), -$646936.0 (Q3 2016), and -$554996.0 (Q2 2016).